Core Insights - Sona Nanotech Inc has reported significant first-in-human results for its targeted hyperthermia therapy, demonstrating tumor elimination in most patients with advanced melanoma who were unresponsive to standard immunotherapy [1][4][8] - The company is transitioning from preclinical research to clinical development, marking a pivotal moment in its growth [3][10] Study Results - The early feasibility study involved ten patients with late-stage melanoma, with eight showing responses and six achieving complete responses [4][8] - Biopsies taken from treated tumors indicated no presence of melanoma within two weeks post-treatment [5] Therapy Mechanism - The therapy utilizes nanoparticles inserted into tumors, activated by a near-infrared laser, which selectively heats cancer cells to around 45 degrees Celsius, causing apoptosis without damaging healthy cells [6][7] - This method enhances the immune system's ability to recognize and attack cancer cells, addressing the limitations of traditional immunotherapies [8][9] Future Plans - The company plans to advance into a Canadian clinical trial, pending Health Canada approval, with insights from the early study informing the next steps [10][14] - Key milestones include further histological analysis and updates on the direction of future studies, with a focus on expanding the therapy's application beyond melanoma [13][14]

Core Insights - Sona Nanotech Inc. reported an 80% response rate in its first-in-human clinical study of Targeted Hyperthermia Therapy (THT) for treating immunotherapy-resistant cutaneous metastatic melanoma, with six out of ten patients achieving complete responses and two showing partial responses within two weeks of treatment [1][2] Group 1: Clinical Study Results - The study involved ten advanced-stage melanoma patients who were not responding to standard immunotherapy, with eight patients showing significant clinical responses by day 15 [1][2] - Six out of the eight responding patients had no detectable residual melanoma in biopsied tumors, while two patients did not respond [1][2] - The rapid response observed in patients has provided meaningful hope for those who had exhausted standard treatment options [2] Group 2: Future Plans and Development - Based on the study findings, the company is preparing for a Canadian clinical trial to explore the biological potential of THT in a broader range of solid tumors, with an application for investigational testing authorization submitted to Health Canada [2] - The company aims to enhance the design and application of THT based on clinician-reported and patient-reported experiences captured during the study [2] Group 3: Safety and Tolerability - Safety data indicated favorable results, with one serious adverse event deemed unrelated to THT and resolved, while two patients expired due to disease progression [2] - The study's outcomes validate earlier preclinical findings and provide compelling evidence of THT's efficacy and tolerability in human cancer treatment [2][3] Group 4: Company Background - Sona Nanotech is focused on developing Targeted Hyperthermia, a photothermal cancer therapy that utilizes therapeutic heat to treat solid tumors, aiming to stimulate the immune system and improve drug delivery to tumors [4][5]

Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments of the first cohort of patients ...

Core Viewpoint - Sona Nanotech Inc. has received approval to conduct a pilot clinical trial for its Targeted Hyperthermia Therapy (THT) aimed at treating late-stage melanoma patients, marking a significant step towards clinical application of its innovative cancer treatment technology [1][2]. Group 1: Clinical Trial Details - The pilot study will involve 30-40 patients and is contingent upon obtaining Investigational Testing Authorization from Health Canada [1][2]. - The anticipated start date for the pilot study is late 2025 or early 2026 [2]. Group 2: Company Background and Technology - Sona Nanotech is focused on developing Targeted Hyperthermia™, a photothermal cancer therapy that utilizes therapeutic heat to treat solid tumors, enhancing drug delivery and immune response [3]. - The therapy involves heating tumors to a range of 42-48°C using infrared light absorbed by gold nanorods, which are designed to be safe and effective [3]. - The company has developed proprietary methods for manufacturing gold nanoparticles that are free from cetyltrimethylammonium (CTAB), reducing toxicity risks associated with other technologies [4]. Group 3: Market Context - Melanoma cases in Canada have tripled over the past 30 years, with over 1,300 deaths annually, highlighting the urgent need for effective treatments [2].